Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 20/20 | 0.65 |
| ▸ | MMP2 | P08253 | 18/20 | 0.65 |
| ▸ | MMP3 | P08254 | 18/20 | 0.65 |
| ▸ | MMP1 | P03956 | 14/20 | 0.65 |
| ▸ | MMP7 | P09237 | 10/20 | 0.65 |
| ▸ | MMP8 | P22894 | 7/20 | 0.65 |
| ▸ | MMP9 | P14780 | 6/20 | 0.65 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809660 | 0.88 | MMP13 (0.64) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL7080925 | 0.88 | MMP13 (0.64) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL7077489 | 0.87 | MMP13 (0.64) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL6289732 | 0.84 | MMP13 (0.59) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL7078213 | 0.83 | MMP13 (0.60) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL7081077 | 0.81 | MMP13 (0.66) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL3250278 | 0.81 | MMP13 (0.74) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL6290466 | 0.81 | MMP13 (0.69) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL6530202 | 0.80 | ADAM17 (0.56) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL6291016 | 0.79 | MMP13 (0.67) | MMP13MMP2MMP3MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144292-A1 | Carbocyclic side chain containing, N-substituted metalloprotease inhibitors | PROCTER & GAMBLE COMPANY, THE | 2003-07-31 | — | — | US | disclosed |
| EP-1265886-A2 | CARBOCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001070720-A2 | CARBOCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144292-A1 | Carbocyclic side chain containing, N-substituted metalloprotease inhibitors | MMP2, MMP3, CMA1 | MMP13 20/4885MMP2 1/4885MMP3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.